News: Merck & Co Inc (MRK)

MRK on New York Consolidated

60.28USD
30 Jan 2015
Change (% chg)

$-1.81 (-2.92%)
Prev Close
$62.09
Open
$61.53
Day's High
$61.93
Day's Low
$60.03
Volume
12,086,924
Avg. Vol
10,494,976
52-wk High
$63.62
52-wk Low
$51.92

Search Stocks
Select another date:

Fri, Jan 23 2015

Europe recommends seven new medicines for approval

LONDON - Europe recommended seven new drugs for approval on Friday, including two antibiotics for skin infections and a new treatment option for HIV.

Europe recommends seven new medicines for approval

LONDON, Jan 23 - Europe recommended seven new drugs for approval on Friday, including two antibiotics for skin infections and a new treatment option for HIV.

Johnson & Johnson's forex warning a sign for rival drugmakers

- Johnson & Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck & Co .

Johnson & Johnson's forex warning a sign for rival drugmakers

Jan 20 - Johnson & Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck & Co.

Exclusive: Merck funds tests of lower Zilmax doses as seen seeking way to resume sales

CHICAGO - Merck & Co Inc is funding the testing of lower dosages of its controversial cattle growth drug Zilmax, in a move that livestock experts say is crucial if the company is to resume sales of the product to the U.S. beef industry.

Lilly to test combinations with Merck, Bristol-Myers' cancer drugs

- Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs.

Lilly to test combinations with Merck, Bristol-Myers' cancer drugs

Jan 13 - Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs.

Merck, Bristol heat up immunotherapy race in lung cancer

- Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and AstraZeneca to play catch-up.

Merck, Bristol heat up immunotherapy race in lung cancer

Jan 12 - Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and AstraZeneca to play catch-up.

Merck speeds up drug-submission plans for Hep C, lung cancer

- Merck & Co said it would fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval.

Select another date:
Search Stocks